Market Cap (In KRW)
352.15 Billion
Revenue (In KRW)
3.93 Billion
Net Income (In KRW)
-20.36 Billion
Avg. Volume
868.8 Thousand
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2340.0-6620.0
- PE
- -
- EPS
- -
- Beta Value
- -0.018
- ISIN
- KR7215600008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jaekyung Kim
- Employee Count
- -
- Website
- https://www.sillajen.com
- Ipo Date
- 2016-12-06
- Details
- SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
More Stocks
-
SAMCO
-
1110
-
0HH6Aqua Metals, Inc.
0HH6
-
4839Wowow Inc.
4839
-
FRZAForza X1, Inc.
FRZA
-
2982
-
GREATGreater Than AB
GREAT
-
FC9